Dalvance
Generic name: dalbavancin
Treatment for: Skin and Structure Infection
Pfizer to Withdraw Global Marketing Applications for Dalbavancin
Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
NEW YORK--(BUSINESS WIRE)--Sep 9, 2008 - Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA).
Following feedback from regulatory authorities, the company plans to conduct an additional Phase 3 clinical trial with dalbavancin for the treatment of adults with complicated skin and skin structure infections caused by Gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus). The global multi-center study will generate additional clinical data to support planned future regulatory submissions. A pediatric program with dalbavancin is also planned.
"After careful consideration of feedback and ongoing dialogue with regulatory authorities, Pfizer has decided to study dalbavancin further in patients with complicated skin and skin structure infections," said Dr. Mark Kunkel, Pfizer's Global Medical Therapeutic Area Leader for Anti-infectives and HIV. "Dalbavancin represents a potential important treatment advance and Pfizer is committed to ongoing research of its use in patients who suffer from serious skin infections, including those caused by MRSA."
Dalbavancin, a member of the glycopeptide class of antibiotics, represents an important addition to Pfizer's broad portfolio of antibacterial products and product candidates. Dalbavancin was acquired by Pfizer in September 2005 as part of its acquisition of Vicuron Pharmaceuticals, Inc.
Pfizer has a long history of developing new medicines for treating infectious diseases and remains committed to providing physicians with this important new treatment option. FDA-approved products, including Pfizer's ZYVOX(R) (linezolid IV/Oral), are currently available for the treatment of complicated skin infections caused by MRSA.
MRSA is a virulent and potentially deadly bacterium, and MRSA infections caused by this bacterium are on the rise in hospitals, long-term care facilities and within communities. MRSA is resistant to many classes of commonly used antibiotics and can cause several types of infections, with skin infections being the most common. The Infectious Diseases Society of America (IDSA) has included MRSA on a reported Hit List of top-priority, dangerous drug-resistant microbes that require additional research and new treatments.
DISCLOSURE NOTICE: The information contained in this release is as of September 9, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about a product candidate, Dalbavancin, including its potential benefits and plans for future regulatory submissions, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; the results of the planned additional Phase 3 clinical trial; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for Dalbavancin as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.
Contact
Pfizer Inc
Media:
Shreya Jani, 212-733-4889
Investor:
Suzanne Harnett, 212-733-8009
Posted: September 2008
Related articles
- Dalvance (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients - July 23, 2021
- Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for Dalvance (dalbavancin) - January 21, 2016
- FDA Approves Dalvance (dalbavancin) to Treat Skin Infections - May 23, 2014
- FDA Advisory Committee Unanimously Recommends Approval of Dalvance (dalbavancin) - March 31, 2014
- Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance (dalbavancin hydrochloride) - November 26, 2013
- Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - September 26, 2013
- Pfizer Receives Approvable Letter from FDA for Dalbavancin - December 21, 2007
- Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark Office - June 2, 2005
- Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug Application - May 11, 2005
- Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue Infections - February 24, 2005
- Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration - December 21, 2004
Dalvance (dalbavancin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
